Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures' Acquisition of Lumos Pharma
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 12 2024
0mins
Should l Buy ?
Source: Newsfilter
Lumos Pharma Tender Offer Completion: Lumos Pharma successfully completed a tender offer for its shares at $4.25 each, resulting in the acquisition of approximately 75.62% of its outstanding shares by Double Point Ventures (DPV), allowing DPV to finalize the merger without additional stockholder votes.
Post-Merger Operations: Following the merger, Lumos Pharma will operate as a standalone business under DPV from Austin, Texas, with its common stock ceasing to trade on NASDAQ and shareholders receiving cash and contingent value rights for their un-tendered shares.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
